---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007304"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:07:35.897829+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5

## Summary
- Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.
- Ineligible for 180-day cure period due to reverse stock splits >250:1 cumulative ratio in prior two years.
- Hearing before Nasdaq Panel scheduled for Nov 5, 2024; automatically stays suspension or delisting pending hearing.
- No assurance that Panel will grant an additional compliance extension beyond the hearing date.

## SEC filing metadata
- accession: 0001683168-24-007304
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007304/0001683168-24-007304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007304/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007304
- JSON: https://secwatch.observer/filing/0001683168-24-007304.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.